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ABSTRACT 
The Drosophila dromyosuppressin peptide (TDVDHVFLRFamide) is a member of a family 
of peptides containing the common C-terminal sequence -RFamide. Dromyosuppressin shares a 
high degree of sequence homology with leucomyosuppressin isolated from cockroach 
(pEDVDHVFLRFamide) and identity with neomyosuppressin isolated from fleshfly. By means 
of sequence-specific antisera, the cellular expression pattern of dromyosuppressin immunoreac- 
tive material was determined for all stages of Drosophila development. 
Dromyosuppressin immunoreactivity first appears in two cells of the medial protocere- 
brum in embryos. The larval stage is characterized by an increase in the number of dro- 
myosuppressin immunoreactive cells in the brain and the first appearance of cellular expression 
in the ventral ganglion. Immunoreactive fibers extend from the medial protocerebrum cells into 
the ventral ganglion. Relative to the larval stage, the pupal and adult stages are marked by an 
increase in the number of immunoreactive cells in the central nervous system and an increase 
in the arborization of immunoreactive fibers extending from these cells. 
Immunoreactivity is present in larvae in two cells near the anus; in the adult gut, 
expression is observed in two cells in the rectum and immunoreactive fibers in the crop that 
appear to extend from the central nervous system. In general, the number of cells containing 
dromyosuppressin immunoreactive material increases throughout Drosophila development. 
However, expression in three cells is restricted to specific developmental periods. These data 
identify dromyosuppressin as a brain-gut peptide regulated at both a cellular and developmen- 
tal level. o 1993 Wiley-Liss, Inc. 
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The tetrapeptide FMRFamide was first isolated and 
identified from mollusc as a cardioexcitatory peptide by 
Price and Greenberg ('77). Since that time, antisera to 
FMRFamide have been used to identify immunoreactive 
materials in neural tissue of both vertebrates and inverte- 
brates. Many of the FMRFamide immunoreactive materials 
isolated from vertebrates and invertebrates contain the 
C-terminal sequence of -MRFamide or -LRFamide, and the 
entire family of peptides is structurally related by the 
common C-terminal sequence -RFamide. Studies to date 
have demonstrated that -RFamide peptides represent an 
abundant, phylogenetically widespread peptide family. Tis- 
sue distribution and activity studies suggest that these 
peptides act as transmitters, regulators, and modulators in 
the central nervous system and function in a broad range of 
important physiological processes. 
Drosophila melanogaster genes encoding -RFamide pep- 
tides include: drosulfakinin (Dsk) and FMRFamide. The 
Dsk gene encodes two -MRFamide-containing peptides 
designated DSK I and DSK I1 (Nichols, '87; Nichols et al., 
'88), and the FMRFamide gene encodes a protein that may 
be processed to five different -FMRFamide-containing pep- 
tides (Nambu et al., '88; Schneider and Taghert, '88). Of the 
five -RFamide-containing peptides isolated from an extract 
of adult Drosophila melanogaster (Nichols, '92a), four 
contain -MRFamide and can be predicted from Dsk or 
FMRFamide. The fifth peptide, TDVDHVFLRFamide, is 
not encoded in either Dsk or FMRFamide. 
TDVDHVFLRFamide shares a high degree of sequence 
homology with peptides isolated from chicken (Dockray et 
al., '83), cockroach (Holman et al., '861, fleshfly (F6nagy et 
al., '921, locust (Robb et al., '89), and snail (Ebberink et al., 
'87). The fruitfly and fleshfly peptides are identical, while 
the cockroach, fruitfly, and locust peptides differ only by the 
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N-terminal amino acid residue. The cockroach and fleshfly 
peptides both inhibit gut motility and have been named 
leucomyosuppressin and neomyosuppressin, respectively. 
On the basis of sequence homology, the fruitfly peptide has 
been designated dromyosuppressin. 
Although FMRFamide immunoreactivity has been local- 
ized to a certain subset of neurons in the Drosophila 
nervous system (White et al., '86; Chin et al., '90; Schneider 
et al., '91; O'Brien et al., '91), antisera to FMRFamide 
recognize DSK peptides, FMRFamide-containing peptides, 
TDVDHVFLRFamide, and other -RFamide-containing pep- 
tides. Because the complexity of the -EFamide peptide 
family makes these immunohistochemical data ambiguous, 
it is difficult to interpret results obtained by using antisera 
to FMRFamide or any other antigen with the common 
C-terminal sequence -RFamide. It is important to isolate 
and determine the structure of the naturally occurring 
peptides and design sequence-specific antigens to deter- 
mine the cellular expression patterns of a specific peptide. 
Immunohistochemical studies will provide information on 
the neural tracts containing peptides, thus allowing the 
construction of an anatomical map for the peptides. These 
data may provide information regarding possible sites of 
action and suggest biological function(s1. 
This study was undertaken to determine the developmen- 
tal expression pattern of dromyosuppressin in the central 
nervous system and gut. To identify dromyosuppressin 
immunoreactive material, sequence-specific antisera were 
generated and affinity purified, and cross reactivities deter- 
mined. This manuscript presents data demonstrating that 
dromyosuppressin expression in the Drosophila central 
nervous system begins in the late embryo and continues 
throughout development with an increase in the 
number ofcells, arborization o~~mmunoreact~ve fib rs, and 
intensity of staining. In addition, dromyosuppressin immu- 
noreactive material is observed in both larval and adult gut. 
Fig. 1. Expression in the larval centrd nervous system (dorsal 
view): less than 5 hours. Signal is observed in two medial protocere- 
brum cells (MP2; arrows) and fibers that project from the cells and 
extend into the ventral ganglion, Bar = 50 CLm. 
MATERIALS AND METHODS 
Staging flies 
Drosophila melanogaster Oregon R flies were raised on 
cornmeal molasses media and maintained at 25°C. Adults 
were collected 4 to 6 hours after eclosion, and tissue was 
dissected from 1-2, 5-7, and 11-13 day old adults. Prepu- 
pae were collected and central nervous systems dissected 
from 23-25, 48, 72, and 94 hour old pupae. Larvae were 
collected by allowing flies to lay eggs on grape juice medium 
plates for 21-22 hours, after which the flies were removed 
and all larvae were discarded. After 1 hour, all larvae were 
collected; this was repeated over several hours to establish a 
range of ages. Larvae were dissected at less than 5 hours 
and at 5 hour intervals for ages 15-95 hours. Embryos, 
collected on grape juice medium plates, were dissected at  
111/2-13,13-16, and 16-20 hours. All developmental stages 
were verified by morphological changes and no fewer than 
12 preparations were examined for each time period. 
Antisera production and purification 
TDVDHVC was synthesized by means of an Applied 
Biosystems model 430A solid phase peptide synthesizer and 
purified by preparative reversed-phase high performance 
liquid chromatography (HPLC). The structure of the syn- 
thetic peptide was confirmed by mass spectrometry, amino 
acid analysis, and automated Edman degradation. Antisera 
were raised in two New Zealand White rabbits to TDVDHVC 
conjugated to thyroglobulin through the cysteinyl residue 
of the peptide with N-(4-carboxycyclohexylmethyl-)- 
maleimide, a heterobifunctional crosslinker (Yoshitake et 
al., '79). The initial immunizations were by subcutaneous 
injections, at  multiple sites, of a total of 1 mg of antigen 
emulsified in Freund's complete adjuvant. Subsequent 
boosts were given every 2 weeks by subcutaneous injections 
of a total of 0.5 mg of antigen in Freund's incomplete 
adjuvant. Antisera titers were analyzed by indirect immuno- 
fluorescence of whole mount third instar larval central 
nervous systems as described (White et al., '86). 
A peptide affinity column was made by coupling a 
TDVDHV-MAP, where MAP represents multiple antigenic 
peptide (Posnett and Tam, '89), to AfF-gel 10 (Bio-Rad 
Labs) in dry dimethyl sulfoxide and 1% triethylamine. The 
amount of peptide coupled to the affinity resin was 2 mg 
peptide/ml resin. To purify antisera the column was first 
washed with 10 column volumes of 5 mM sodium phos- 
phate, pH 7.2, prior to antisera application, and then crude 
antisera diluted 1:l with 10 mM sodium phosphate, pH 7.2, 
were applied to the column at a flow rate of 10 mlihr; the 
column was then washed with 10 column volumes of 5 mM 
sodium phosphate, pH 7.2. The binding capacity of the 
column exceeded the amount of antisera applied. 
TDVDHV-specific antisera were eluted from the column 
with 5 column volumes of 0.1 M sodium citrate, pH 2.5, and 
the eluant was neutralized by collecting directly into 10 
volumes of 1 M Tris, pH 8.0 and subsequently dialyzed 
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Fig. 2. Expression in the larval central nervous system (dorsal view): A: 20 hours. B 25 hours. The 
fibers that extend from the MP2 cells into the ventral ganglion begin to send out imrnunoreactive 
projections (open arrows in A and B). Two cells in the superior protocerebrum (SP3; B) express 
dromyosuppressin. No signal is observed in the ring gland (rg; B). Bars = 50 pm. 
against 4 liters of 0.01 mM sodium phosphate, pH 7.2, at  
4°C for 24 hours. The affinity-purified antisera were then 
aliquoted, freeze-dried, and stored at  -20°C. 
Immunohistochemistry 
Tissue was dissected in cold Ringer's solution and pre- 
pared for immunohistochemistry according to White et al. 
('86). Whole mount preparations fixed in paraformaldehyde 
and washed in PTN (0.5 M sodium phosphate, pH 7.2 
containing 10% Triton X-100 and 1% sodium azide) were 
incubated for 2 hours or more at 4°C with affinity-purified 
antisera, washed extensively in PTN, and then incubated 
for 2 hours or more a t  4°C with fluorescein isothiocyanate 
(F1TC)-labeled goat anti-rabbit antibody (Sigma). Controls 
included no primary antibody, no second antibody, and 
primary antibody preincubated for 2 hours or longer with 
FDDYGHMRFamide (DSK I), TDVDHVFLRFamide, or 
FMRFamide at concentrations ranging from 0.0001 M to 
0.005 M. 
Antisera specificity 
The specificity of the antisera was determined by the 
choice of antigen, affinity purification, and incubation of the 
antisera with peptides prior to immunohistochemistry. The 
antigen used, TDVDHVC, is the N-terminal portion of 
common C-terminal sequence -RFamide. The peptide also 
includes a cysteinyl residue as a site for chemically linking a 
carrier. TDVDHV-specific antisera were purified from the 
whole sera on a TDVDHV-MAP affinity column. Experi- 
ments using antigen-inactivated antisera indicate that fluo- 
rescence is from dromyosuppressin-like material since pre- 
incubation of the antisera with TDVDHVFLRFamide 
completely abolished all signal, while preincubation of the 
antisera with FDDYGHMRFamide (DSK I) or FMRFamide 
did not alter the pattern or intensity of fluorescence 
observed (data not shown). Larval preparations incubated 
with either primary or secondary antisera alone did not 
result in observable fluorescence. Also, the immunoreactiv- 
ity was restricted to a defined set of neurosecretory cells. 
RESULTS 
The terminology for comparing the cells expressing dro- 
myosuppressin to those expressing FMRFamide-like mate- 
rials is from White et d. ('86), Schneider et al. ('911, and 
O'Brien et al. ('91). The description of the number of 
immunoreactive cells in the central nervous system takes 
into account the observation that the cells and fibers were 
all bilaterallv svmmetric to the midline. i.e.. the reDort of " "  
immunoreactivity in one cell indicates that two imminore- 
active cells bilaterally symmetric to each other were pres- TDVDHVFLRFamide, which avoids raising antisera to the 
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Fig. 3. Expression in the larval central nervous system (dorsal 
view): A: 55 hours. B: Greater than 65 hours. The immunoreactive 
fibers that extend from the MP2 cells into the ventral ganglion begin to  
send out immunoreactive projections (open arrow; A). SP3 cells send 
immunoreactive fibers to the ring gland (large arrowhead in A and B). 
An immunoreactive fiber is seen to project from the abdominal ganglia 
(solid arrow in A and B). T1-3, VC, and A8 cells that appear in the 
ventral ganglion are illustrated by bars, small arrowheads, and open 
white arrows, respectively (B). Bars = 50 pm. 
ent. The signal intensities were strong except where 
specifically mentioned. 
Expression of dromyosuppressin 
immunoreactive material in the embryonic 
central nervous system 
No fluorescence signal was observed in embryos at  stage 
15 (11.5-13 hours). However, faint signals were observed at  
stages 16 (13-16 hours) and 17 (> 16 hours) in the brain 
lobes in two cells in the medial protocerebrum and fibers 
that project from the cell bodies into the ventral ganglion 
(data not shown). 
Expression of dromyosuppressin 
immunoreactive material in the larval central 
nervous system 
Fluorescence was observed in larvae at  less than 5 hours 
in the two medial protocerebrum cells (MP2) and the fibers 
projecting from these cells as well as in two neurosecretory 
cells (SP3) located in the superior protocerebrum (Fig. 1). 
The cells are identified as MP2 and SP3 from double- 
labeling experiments using DSK-specific and TDVDHV- 
specific antisera (Tibbetts and Nichols '93). 
At 15-20 hours, the immunoreactive fibers that project 
from the MP2 cells into the ventral ganglion began to 
branch and become more complex (Fig. 2). Although the 
significance of the pattern formed by these immunoreactive 
Fig. 4. Expression in the larval superior protocerebrum and sub- 
esophageal ganglion (dorsal view). Signals are observed in the superior 
protocerebrum in cells tentatively identified as SP2 cells (horizontal 
arrows) and in SP3 cells (vertical arrows). The MP2 cells (small white 
arrows) are out of focus because a whole mount preparation was used. 
Open arrows point to cells in the subesophageal ganglion. Bar = 50 pm. 
fibers is not known, it is likely that this configuration allows 
for release of the peptide directly onto as yet unidentified 
target cell(s). In early larvae, signal from the SP3 cells was 
faint but during larval development the signal intensified, 
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Fig. 5. Expression in the pupal brain (dorsal view). Signal is present in SP3 (black arrows), MP2 (short 
white arrows), and two sets of optic lobe cells (long white arrows). Bar = 50 km. (The figure represents one 
focal plane.) 
and immunoreactive fibers can be observed to project from 
the SP3 cells into the ring gland (Fig. 3). 
Immunofluorescence appears in ventral ganglion cells 
that are similar in position to T1-3, A8, and VC cells 
containing FMRFamide-like immunoreactive material. T 1-3 
represents three individual cells, T1, T2, and T3, laterally 
positioned one cell in each of the three thoracic ganglia, A8 
is a single cell in the posterior tip of the ganglion, and VC is 
a chain of approximately seven cells along the midline of the 
ventral ganglion (Fig. 3). None of the ventral ganglion cells 
appeared to have immunoreactive fibers, as observed for 
the cells in the protocerebrum. The intensity of the signal 
observed was significantly less than that observed for the 
MP2 and SP3 cells. It is not possible from these experi- 
ments to determine whether the difference in intensity is 
due to the amount of peptide expressed or the affinity of the 
antisera for the antigen(s) present. 
During larval development there was an increase in the 
number of cells in the central nervous system containing 
immunoreactive material with the addition of a cell in the 
subesophageal ganglion and two more cells in the superior 
protocerebrum (Fig. 4). Overall, the expression of dromyo- 
suppressin immunoreactive material in the larval stage 
began with just two cell types and progressed to seven. 
There was a marked increase in the number of immunoreac- 
tive cells and the signal intensity with the exception that 
the signal in the subesophageal cell became less intense 
during the latter part of the larval stage. 
Expression of dromyosuppressin 
immunoreactive material in the pupal central 
nervous system 
Early pupal expression was distinguished by the loss of 
signal in the superior protocerebrum cells and one of the 
two MP2 cells, while at the same time two sets of optic lobe 
cells and two ventral medial subesophageal cells appeared 
(Fig. 5). As the pupae developed, the number of SP3 cells 
increased to six and the arborization of the SP3 immunore- 
active fibers increased (Fig. 5). The subesophageal cell seen 
in larvae was not observed in the pupal stage. However, it is 
important to note that it is difficult to distinguish the 
different subesophageal cells from one another. The ventral 
medial subesophageal cells expressing dromyosuppres- 
sin are similar in position to the SVM cells containing 
FMRFamide-immunoreactive materials. 
Signal was still observed in cells of the ganglion; however, 
the immunoreactive fibers were more prominent (Fig. 6). 
The reduction of cellular signal may, in some part, have 
resulted from the thickness of the tissue preparations. 
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Fig. 6. Expression in the pupa (dorsal view): subesophageal ganglion (A) and ventral ganglion (B). 
Signal is observed in cells tentatively identified as SVM cells (small white arrows) and a cluster of SC cells 
near the esophagus (large white arrow) in the subesophageal ganglion (A). Signal is observed in cells and 
fibers in the ventral ganglion (B). Bars = 50 pm. 
Expression of dromyosuppressin 
immunoreactive material in the adult central 
nervous system 
In general, the cellular pattern of immunoreactivity in 
the adult was similar to that of the late pupal stage (Fig. 7). 
However, signal intensity and arborization of immunoreac- 
tive fibers increased significantly, and there was a dramatic 
increase in signal from the varicosities associated with the 
immunoreactive fibers observed with the adult age (Figs. 7, 
8). Cells in a similar position as SC cells were more apparent 
than in pupae, and an optic lobe cell displayed an increased 
arborization similar to that observed in the blowfly (Nassel 
et al. '88). 
In addition, dromyosuppressin expression was seen in a 
cell near the position where SP2 cells are located (Fig. 7). 
This finding led to the question of whether immunoreactiv- 
ity in SP2 returns in the adult after disappearing in the 
pupal stage or if this was a different but similarly positioned 
cell. Although the exact identity of the cell based on position 
was difficult to establish in a whole mount preparation, the 
observation remains an interesting question since expres- 
sion either returns in only one of the two SP2 cells observed 
during the larval stage or else begins late in development in 
a cell not previously seen to express the peptide. 
While dromyosuppressin expression in a subesophageal 
cell thought to be SE was present during the larval stage 
and absent during the pupal stage, a weak signal was 
inconsistently observed in the adult. Because the intensity 
of the signal was low, the question remains as to the exact 
identity of the cell and the pattern of expression in the SE 
cell. 
The immunoreactivity in the adult ganglion was very 
similar to that observed in pupae: the signal was mainly 
from varicosities of the immunoreactive fibers while cellu- 
lar expression was present but less intense. 
Expression of dromyosuppressin 
immunoreactive material in larval and adult 
gut tissue 
Although no immunoreactivity was seen in the larval 
proventriculus, midgut, or hindgut, immunoreactivity is 
observed in two cells near the anus (Fig. 9). Relative to one 
another, the two cells in the larval gut are at very different 
focal planes, which may indicate that the larval cells are on 
opposite sides of the anus. 
In the adult gut, immunoreactivity was seen in two cells 
of the rectum (Fig. 10). Similar to the larva, the cells 
appeared in very different focal planes, suggesting that they 
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Fig. 7. Expression in the adult central nervous system (dorsal view): 6 days. Signal is observed in the 
SP3 and MP2 cells, and cells in the optic lobe and subesophageal ganglion. An open arrow points to a cell in 
the region of SP2 (refer to text). Bar = 50 km. 
too may be located on opposite sides of the rectum. Immuno- 
reactive fibers extending from the central nervous system 
were observed in the crop. 
The absence of immunoreactivity in the remaining re- 
gions of both the adult and larval gut was further examined. 
In addition, larvae and adults were analyzed for immunore- 
activity outside of the central nervous system and gut. Two 
approaches were used to monitor the quality of experiments 
and presence of signal: 1) central nervous systems were 
incubated along with the gut tissue; and 2) DSK I antisera 
that localize to the midgut (Nichols, '92b) were used. These 
studies indicated that the lack of signal in the midgut was 
not due to technical difficulties (data not shown). In addi- 
tion to the control studies, the high signal to low back- 
ground staining in the gut preparations suggest that no 
immunoreactivity went unobserved. No cell expressing 
dromyosuppressin was observed in tissue other than the 
central nervous system and gut. 
DISCUSSION 
The insect brain contains neurosecretory cells that differ 
from other neurons by the presence of membrane-bound 
secretory granules and are thought to make use of biologi- 
cally active peptides as messenger substances (Scharrer, 
'58, '59, '82). To learn about the role(s) of peptidergic 
neurons in Drosophila brain, we have undertaken the task 
of isolating and identifying the structure of naturally 
occurring peptides containing -RFamide and determining 
cellular expression by using sequence-specific antisera. The 
expression pattern of specific neuropeptides used in conjunc- 
tion with genetic and molecular studies may provide the 
opportunity to determine peptide function(s1. 
Sequence-specific antisera were used to determine the 
developmental expression pattern of dromyosuppressin, an 
abundant peptide isolated from Drosophila. Dromyosuppres- 
sin expression began early in development in the embryonic 
central nervous system and had a net increase in both the 
number of cells and signal intensity through development. 
Immunoreactivity was first observed in the brain and then 
in the ventral ganglion. At each of the numerous time 
points studied, signals were observed suggesting that the 
neuropeptide gene is expressed without disruption through- 
out Drosoph ila development. While the vast majority of 
cells continue to express dromyosuppressin, the expression 
in three cells-a MP2 cell, and cells in similar positions to a 
SE cell and the SP2 cells-was restricted to specific develop- 
mental periods. 
The patterns of gut expression in larva and adult are 
similar, suggesting that the peptide may serve a similar 
function at both stages. In addition, immunoreactive fibers 
are observed in the crop, an adult structure that utilizes 
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Fig. 8. Expression in the adult central nervous system (dorsal view): 11 days. Increased signal intensity 
is observed in the older aduit central nervous system. (Signal originates from one MP2 cell.) Bar = 50 km. 
extensive muscle activity. The presence of dromyosuppres- 
sin immunoreactivity in the gut as well as the central 
nervous system indicates that control of gene expression is 
tissue-specific as well as developmental and that dromyosup- 
pressin is a brain-gut peptide. 
The question of whether DMS and other peptides contain- 
ing -RFamide are expressed in the same cells is interesting 
from functional and regulatory aspects. Dromyosuppressin 
appears to be expressed in some of the same cells that have 
been identified as containing FMRFamide immunoreactive 
material. However, since antisera to FMRFamide recognize 
DMS and DSK peptides as well as the five -FMRFamide- 
containing peptides encoded in the FMRFamide gene, the 
immunohistochemical data obtained using antisera to 
FMRFamide are ambiguous, and the cellular expression 
patterns of the FMRFamide gene products are not known. 
Meola and co-workers used antisera raised to the cock- 
roach leucomyosuppressin peptide to study leucomyosup- 
pressin-like immunoreactivity in the adult stable fly (Meola 
et al., '91). The expression pattern differs between fruitfly 
and stable fly, with the majority of leucornyosuppressin-like 
immunoreactivity in stable fly observed in the thoracic 
ganglion. The basis of the difference in expression between 
the fruitfly and the stable fly is not clear. However, 
Dossibilities mav include a difference in mecies-mecific 
ixpression and/or differences in the avidity 0: the antisera. 
i t Y  was observed in stable flY earlier in development O r  in 
Fig, 9, Expression in the larval gut (dorsal view). A: Two immunore- 
arrow ooints to the uosterior miracles). BE: Enlargements of the same 
No information was reported as to whether immunoreactiv- active cells (white arrows) near the posterior of the larval gut (an open 
the gut. cells. Bars = 50 Kin.  
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Fig. 10. Expression in t h e  adult: A: Central nervous system, 
proventriculus, and  crop. B: Rectal cells. Immunoreactive fibers oh- 
served in  the  crop (A) extend from the  central nervous system. At two 
different planes of focus, illustrated by B and C, two immunoreactive 
cells and fibers projecting from the cells can be observed in  the rectum. 
Bars = 50 bm. 
Dromyosuppressin shares a high degree of sequence 
homology with other invertebrate peptides. As to the 
function of these highly conserved peptides, leucomyosup- 
pressin (Holman et al., '86) and neomyosuppressin (F6nagy 
et al., '921, both inhibit spontaneous contraction of isolated 
hindgut. The locust peptide produces a complex, dose- 
dependent pattern of potentiation and inhibition on the 
extensor-tibiae muscle and is a potent cardioinhibitory 
agent that suppresses spontaneous contractions in semi- 
isolated heart preparations (Robb et al., '89). These activi- 
ties may reflect the complexity of possible actions, differ- 
ences in function in different insects, or the assay 
preparations used. 
Although assay systems can provide significant informa- 
tion concerning a potential role, it will be important to 
study the roles of the naturally occurring peptide in the 
organism itself. The widespread tissue distribution sug- 
gests that this molecule may act in a variety of physiological 
processes. I t  remains to be established what action the 
287 
peptides exert in vivo. Drosophila melanogaster provides 
the opportunity to utilize an organism amenable to genetic 
manipulation as well as biochemistry, molecular biology, 
and physiology to study the role(s) of this peptide with the 
possibility of elucidating function. 
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